Skip to content

The Effects of Sedating Medications on the levels of Physiological Stress in Critically Unwell Patients

Allostasis and Sedation Practices in Intensive Care Evaluation (All-SPICE) - A substudy of a Randomised multi-centre Sedation Practices in Intensive Care Evaluation (SPICE-III) study, to determine the effect of sedation medications on levels of physiological stress

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12616001200471
Acronym
All-SPICE
Enrollment
46
Registered
2016-08-31
Start date
2017-04-18
Completion date
2017-10-30
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The survival of an organism in the face of internal and external events requires a measured and appropriate stress response. It has been hypothesised that an abnormal stress response is linked to the likelihood of the development and severity of critical illness and multi-organ failure. The stress response is coordinated by the primitive brain structures of the diencephalon and brainstem in response to somatosensory inputs and comprises a broad range of neuro-hormonal and immune effects. We hypothesise that the use of sedating medications confuses the normal generation of a stress response. If this is confirmed, this may be a fundamental underlying cause for the abnormal haemodynamics, metabolic disturbances and organ dysfunction observed in critical illness. The large multi-centre randomised-controlled SPICE-III study offers the opportunity to study two similar groups of patients who may have differing levels of physiological stress as a result of an Early Goal-Directed Sedation (EGDS) strategy as compared to standard care. We aim to conduct a substudy to determine whether a strategy of EGDS and the resultant reduced sedation level results in a differing physiological stress response in critically unwell patients as measured by a panel of blood-borne markers. We hypothesise that the application of an early goal directed sedation protocol and the resultant reduced sedation level in the first 5 days of critical illness will result in a differing pattern of stress as measured by metabolic, sympathetic, hormonal and inflammatory responses. All-SPICE will be a prospective parallel-group multi-centre observational sub-study of the the SPICE-III study. The SPICE-III study is a prospective, un-blinded, randomised controlled trial of Early Goal-Directed Sedation compared with Standard care. The SPICE-III study will recruit patients who are intubated and ventilated in a participating ICU, are expected to remain intubated the day after enrolment and need immediate and ongoing sedation. Due to the immediate need to choose a sedative regimen for ongoing patient safety and comfort, it is proposed that study enrolment will occur using deferred consent. A total of 100 patients from approximately 4 ICUs will be enrolled in All-SPICE. Immediately following randomisation on day 1, patients will have blood samples taken, which will be repeated on days 2, 4 and 6. These samples will be assessed for various blood-borne markers which are considered to be potentially affected by the coordination of the stress response.

Interventions

All-SPICE will be a prospective parallel-group multi-centre observational substudy of SPICE-III utilising the the SPICE-III study screening. The SPICE-III study (NCT01728558) is a prospective, un-blinded, randomised controlled trial of Early Goal-Directed Sedation compared with Standard care and will recruit 4000 patients worldwide. The SPICE-III study will recruit patients who are intubated and ventilated in a participating ICU, are expected to remain intubated the day after enrolment and need

All-SPICE will be a prospective parallel-group multi-centre observational substudy of SPICE-III utilising the the SPICE-III study screening. The SPICE-III study (NCT01728558) is a prospective, un-blinded, randomised controlled trial of Early Goal-Directed Sedation compared with Standard care and will recruit 4000 patients worldwide. The SPICE-III study will recruit patients who are intubated and ventilated in a participating ICU, are expected to remain intubated the day after enrolment and need immediate and ongoing sedation. Following recruitment, patients will be randomised to either the intervention arm, Early Goal-Directed Sedation (EGDS) or the control arm, standard sedation practice (STDS). Patients in the EGDS arm will receive a dexmedetomidine infusion starting at 1 mcg/kg/hr without loading dose to achieve a target Richmond Agitation Sedation Scale (RASS) [10] -2 to +1 at all times, unless otherwise clinically indicated. If dexmedetomidine alone is insufficient, propofol will be administered, by bolus or infusion (10-70 mg/hr) or both, to achieve the targeted level of sedation. Patients in the STDS will receive sedative medications (either midazolam or propofol or both), as determined by the treating clinician, to achieve clinically appropriate sedation target as chosen by the treating clinician, although a target of RASS -2 to +1 is encouraged (default) at all times in this arm. Patients enrolled in the SPICE-III study will be eligible for inclusion in the All-SPICE sub-study. A total of 100 patients from approximately 4 ICUs will be enrolled in All-SPICE. Immediately following randomisation on day 1, patients will have blood samples taken, which will be repeated on days 2, 4 and 6.

Sponsors

Sunshine Coast Hospital and Health Service
Lead SponsorGovernment body

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Enrolled in the SPICE-III study

Exclusion criteria

Nil

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 24, 2026